Recent trends in stimulant medication use among US children

Division of Services and Intervention Research, NIMH, 6001 Executive Blvd., Bethesda, MD 20892-9633, USA.
American Journal of Psychiatry (Impact Factor: 13.56). 05/2006; 163(4):579-85. DOI: 10.1176/appi.ajp.163.4.579
Source: PubMed

ABSTRACT Stimulant medications, such as methylphenidate and amphetamines, are commonly prescribed to treat attention deficit hyperactivity disorder. Stimulant use increased fourfold from 1987 (0.6%) to 1996 (2.4%) among subjects 18-year-old and younger in the U.S. The aim of this study was to determine whether pediatric use of stimulants continued to rise during the period 1997-2002.
The Medical Expenditure Panel Survey (MEPS) database for the years 1997-2001 was analyzed. The MEPS is a yearly survey of a nationally representative sample of civilian, noninstitutionalized U.S. households, conducted by the U.S. Agency for Health Care Research and Quality. Previously reported estimates from the 1996 MEPS and the 1987 National Medical Expenditure Survey, the predecessor to MEPS, were also replicated to compare recent trends to changes between 1987 and 1996.
The prevalence use of stimulants among subjects under 19 years of age was 2.7% (95% C.I. 2.3-3.1) in 1997 and 2.9% (95% C.I. 2.5-3.3) in 2002, with no statistically significant change during these 6 years. Likewise, when pooling data across years and comparing the rate in 1997-1998 (2.8%) with the rate in 2001-2002 (3.0%), no statistically significant changes emerged. Use was highest among 6-12 year olds (4.8% in 2002), as compared with 3.2% among 13-19 year olds and 0.3% among children under 6. An estimated 2.2 million (95% C.I. 1.9-2.6) children received stimulant medication in 2002 as compared to 2.0 million (95% C.I. 1.7-2.3) in 1997.
The steep increase in the utilization of stimulants among children 18 years and younger that occurred over the 1987-1996 period attenuated in the following years through 2002, and has remained stable among very young children.

Download full-text


Available from: Benedetto Vitiello, Jul 06, 2015
  • Source
    Journal of Behavioral and Brain Science 08/2014; 4(08):375-383. DOI:10.4236/jbbs.2014.48036
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Methylphenidate (MPH) is one of the most commonly used and highly effective treatments for attention deficit hyperactivity disorder (ADHD) in children and adults. As the therapeutic use of MPH has increased, so has its abuse and illicit street-use. Yet, the mechanisms associated with development of MPH-associated abuse and dependence are not well understood making it difficult to develop methods to help its mitigation. As a result, many ADHD patients especially children and youth, that could benefit from MPH treatment do not receive it and risk lifelong disabilities associated with untreated ADHD. Therefore, understanding the mechanisms associated with development of MPH addiction and designing methods to prevent it assume high public health significance. Using a mouse model we show that supra-therapeutic doses of MPH produce rewarding effects (surrogate measure for addiction in humans) in a conditioned place preference paradigm and upregulate μ opioid receptor (MOPR) activity in the striatum and nucleus accumbens, brain regions associated with reward circuitry. Co-administration of naltrexone, a non-selective opioid receptor antagonist, prevents MPH-induced MOPR activation and the rewarding effects. The MPH-induced MOPR activation and rewarding effect require activation of the dopamine D1 but not the D2-receptor. These findings identify the MOPR as a potential target for attenuating rewarding effects of MPH and suggest that a formulation that combines naltrexone with MPH could be a useful pharmaceutical approach to alleviate abuse potential of MPH and other stimulants.
    Neuropharmacology 07/2011; 61(1-2):283-92. DOI:10.1016/j.neuropharm.2011.04.015 · 4.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This case report describes a 10-year-old boy who presented with comorbid stuttering, ADHD and Tourette Syndrome. The focus of this case study is the child's favorable reaction to the non-stimulant Strattera ® versus the stimulant Adderall XR ® on stuttering behaviors. The family reported increased stuttering, tic behaviors, social anxiety and communication related frustration resulting in social isolation shortly after starting the stimulant medication. Consequently, the medical team discontinued the stimulant medication and prescribed the non-stimulant Strattera ® to manage the ADHD symptoms.
    Perspectives on Fluency and Fluency Disorders 11/2009; 19(3):95-98. DOI:10.1044/ffd19.3.95